Oliver Sartor

Last updated
Oliver Sartor
Alma mater Tulane University
Scientific career
Fields Oncology
Institutions Tulane School of Medicine

Oliver Sartor is an American oncologist and research scientist. He is currently the chair of the genitourinary cancer disease group and director of radiopharmaceutical clinical trials at Mayo Clinic Rochester. He was previously the assistant dean for oncology and the C.E. and Bernadine Laborde Professor of Cancer Research, Medicine and Urology Departments at the Tulane School of Medicine in New Orleans, Louisiana. His research has mainly focused on translational science and clinical research trials of advanced prostate cancer since 1990 and he is recognized as an expert in that field through his contributions to the practice and the publishing of over 500 peer-reviewed articles and numerous book chapters and reviews. [1] Sartor also serves as the editor-in-chief of the bimonthly journal Clinical Genitourinary Cancer that mainly focuses on research in genitourinary oncology. [2]

Contents

Education and career

Sartor attended Tulane University, where he received his MD in 1982 with honors. He then served as an intern at the University of Pennsylvania. After the internship, he served a residency in internal medicine at Tulane Medical School and then completed a medical oncology fellowship at the National Cancer Institute (NCI) in 1989. [3]

He joined the faculty at NCI, where he became a senior investigator mainly focusing on novel therapeutics for patients with advanced prostate cancer. He served as faculty at the NCI from 1990 till 1993, when he later returned to Louisiana and joined the faculty of LSU Medical School in Shreveport as an associate professor. [4] [5] In 1998, Sartor became professor of oncology, director at the Stanley S, Scott Cancer Center, and a chief of Hematology/Oncology section at LSU Medical School in New Orleans. He was named the co-director of Louisiana Cancer Research Consortium in 2002. Sartor left LSU after Hurricane Katrina and in 2006 joined the faculty of Harvard Medical School and the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute. [6] [7] In January 2008, Sartor was appointed as professor in the Medicine and Urology Departments at Tulane University. He was later appointed the medical director at the Tulane Cancer Center in July 2010 and has served as assistant dean for oncology since 2016. [8] He has served as medical oncology co-chair of the Genitourinary Committee of NRG (formerly RTOG) since 2006 and has served on the NCI Board of Scientific Counselors (Clinical and Epidemiology) since 2014. [9]

Research

Throughout his academic career, Sartor has worked as a researcher, almost exclusively focused on prostate cancer. He has earned international recognition, particularly as an expert in advanced prostate cancer. He has published extensively on both prostate cancer translational studies and clinical trials that involve novel agents. [10]

Sartor was the PI or co-PI on four prostate cancer studies pivotal for FDA drug approval including Samarium-153 EDTMP, [11] Cabazitaxel, [12] Radium-223, [13] and Leuprolide Acetate 30 mg sustained release (Eligard). [14] In addition he has served as chair of the Data Monitor Committee for numerous phase III trials, including 6 trials pivotal for FDA approval. [15] [ failed verification ]

Related Research Articles

<span class="mw-page-title-main">Urology</span> Medical specialty

Urology, also known as genitourinary surgery, is the branch of medicine that focuses on surgical and medical diseases of the urinary system and the reproductive organs. Organs under the domain of urology include the kidneys, adrenal glands, ureters, urinary bladder, urethra, and the male reproductive organs.

<span class="mw-page-title-main">Chandler Park</span> American physician

Chandler Park is an American physician, medical journalist, and clinical researcher. In June 2021, his cancer research was published in prominent medical journals including the New England Journal of Medicine and Journal of Clinical Oncology. Park also contributes regularly as an expert physician for popular newspapers and magazines such as Newsweek, Reader's Digest, U.S. News & World Report, The Exponent-Telegram, College of St. Scholastica, and Medscape and writes medical news for Doximity.

<span class="mw-page-title-main">Andrew von Eschenbach</span>

Andrew C. von Eschenbach was the Commissioner of the United States Food and Drug Administration from 2006 to 2009. He became acting Commissioner on September 26, 2005, after the resignation of his predecessor Lester Crawford, and was confirmed as Commissioner by the Senate on December 7, 2006. He was previously the 12th director of the National Cancer Institute.

Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as medical director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.

<span class="mw-page-title-main">Enzalutamide</span> Antiandrogen medication used in treatment of prostate cancer

Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC). It is taken by mouth.

James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute.

Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship based interventions. These interventions are focused on five domains including: physical symptoms, psychological symptoms, surveillance, health promotion and care coordination. However, a published review has found only high levels of evidence for interventions that target physical and psychological symptom management and health promotion, with no reviews of interventions for either care coordination or surveillance. The favored treatment option depends on the stage of the disease, the Gleason score, and the PSA level. Other important factors include the man's age, his general health, and his feelings about potential treatments and their possible side-effects. Because all treatments can have significant side-effects, such as erectile dysfunction and urinary incontinence, treatment discussions often focus on balancing the goals of therapy with the risks of lifestyle alterations.

Simon J. Hall is an American researcher who is the Associate Professor and Kyung Hyun Kim, M.D. Chair of Urology and Assistant Professor, Department of Gene and Cell Medicine at The Mount Sinai School of Medicine, as well as the Director of the Barbara and Maurice Deane Prostate Health and Research Center at The Mount Sinai Medical Center, both in New York City.

William K. Oh, is an American medical oncologist, academic and industry leader and expert in the management of genitourinary malignancies, including prostate, renal, bladder and testicular cancers.

<span class="mw-page-title-main">Cabazitaxel</span> Chemical compound

Cabazitaxel, sold under the brand name Jevtana, is a semi-synthetic derivative of a natural taxoid. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.

Dr. Cora Sternberg is an American medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital, serving as a member of the Genitourinary (GU) Oncology Program. Dr. Sternberg facilitates the continued growth and development of clinical and translational research programs in GU malignancies. Dr. Sternberg is an internationally respected leader in the field of medical oncology and urological malignancies and a recognized expert in the area of new drug development. She is known for her seminal contributions in bladder cancer, her strong track record of sustained genito-urinary (GU) oncology leadership and collaboration in multiple practice-changing clinical trials, including novel medicines, and her current role applying her expertise in oncology and GU cancers to precision medicine to further improve outcomes for patients. Dr. Sternberg has been decidedly influential in the development of novel hormonal therapies and checkpoint inhibitors across the landscape of GU oncology as evidenced in her curriculum vitae. She is a globally respected researcher who has lectured extensively at universities and cancer symposia worldwide (>800). As Clinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg develops strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network, including Lower Manhattan, Brooklyn and Queens.

Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food.

<span class="mw-page-title-main">Thomas Hutson</span> American oncologist and cancer researcher

Thomas E. Hutson is an American medical oncologist and cancer researcher based in Dallas, Texas. He is the director of Genitourinary Oncology Program and co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center. He is a Professor of Medicine at the Texas A&M Health Science Center College of Medicine and serves as a chair of Genitourinary Research for US Oncology and McKesson.

Deborah Watkins Bruner is an American researcher, clinical trialist, and academic. She is the senior vice president for research at Emory University. Her research focus is on patient reported outcomes, symptom management across cancer sites, sexuality after cancer treatment, and effectiveness of radiotherapy modalities. Bruner's research has been continually funding since 1998, with total funding of her research exceeding $180 million. She is ranked among the top five percent of all National Institutes of Health-funded investigators worldwide since 2012, according to the Blue Ridge Institute for Medical Research.

<span class="mw-page-title-main">Philip Kantoff</span> Medical researcher

Philip W. Kantoff is a medical oncologist. He is the chairman and chief executive officer (CEO) of Convergent Therapeutics. He served as the Chairman of Medicine at Memorial Sloan Kettering Cancer Center between 2015 and 2021. He is best known for his contributions to the impact of DNA abnormalities in prostate cancer and the discovery of therapies for metastatic hormone-sensitive prostate cancer.

<span class="mw-page-title-main">Andrea Apolo</span> American medical oncologist

Andrea B. Apolo is an American medical oncologist specialized in bladder cancer research. She is an investigator in the National Cancer Institute's genitourinary malignancies branch and head of the bladder cancer section.

Karen E. Knudsen is Chief Executive Officer of American Cancer Society and its advocacy affiliate the American Cancer Society Cancer Action Network. She is the first woman to hold that position in either organization.

Elizabeth R. Plimack is an American medical oncologist. She is a professor in the Department of Hematology/Oncology and Chief of the Division of Genitourinary Medical Oncology at the Fox Chase Cancer Center. In these roles, she researches the treatment of genitourinary malignancies with a focus on bladder and kidney cancers.

Ronald de Wit is a professor of medical oncology at Erasmus University Medical Center in Rotterdam, Netherlands. He is the founding chairman of the Dutch Uro-Oncology Study Group (DUOS).

References

  1. ↑ Sartor, Oliver. "Preliminary Data from the PROCEED Registry- Oliver Sartor". www.urotoday.com. Retrieved 6 September 2018.
  2. ↑ "A. Oliver Sartor, MD | medicine". medicine.tulane.edu. Retrieved 6 September 2018.
  3. ↑ "An Update on New Therapies for mCRPC: Interview with Oliver Sartor, MD". www.renalandurologynews.com. Retrieved 6 September 2018.
  4. ↑ Rosenthal, Eric T. (October 2005). "Rallying to Oncology Patients & Cancer Care Professionals, Two New Orleans Cancer Center Directors Share Their Stories". Oncology Times. 27 (19): 26–28. doi: 10.1097/01.COT.0000289684.23125.e5 .
  5. ↑ Sartor, Oliver (June 2002). "Editorial". Clinical Prostate Cancer. 1: 5. doi:10.3816/CGC.2002.n.001 . Retrieved 6 September 2018.
  6. ↑ "About Oliver Sartor | Tulane Urology Garden District". Tulane Urology Garden District. Retrieved 6 September 2018.
  7. ↑ "Pulled up by his New Orleans roots - The Boston Globe". archive.boston.com. Retrieved 6 September 2018.
  8. ↑ Chustecka, Zosia (February 1, 2012). "MDV3100 in Prostate Cancer 'Exceeded Expectations'". Medscape . Retrieved 6 September 2018.
  9. ↑ "Genitourinary Cancer". www.rtog.org. Retrieved 24 September 2018.
  10. ↑ Kolata, Gina (26 April 2018). "'Desperation Oncology': When Patients Are Dying, Some Cancer Doctors Turn to Immunotherapy". The New York Times. Retrieved 6 September 2018.
  11. ↑ Higano, Celestia S.; Quick, Donald P.; Bushnell, David; Sartor, Oliver (2008). "Safety Analysis of Repeated High Doses of Samarium-153 Lexidronam in Men with Hormone-Naive Prostate Cancer Metastatic to Bone". Clinical Genitourinary Cancer. 6 (1): 40–45. doi:10.3816/CGC.2008.n.007. ISSN   1558-7673. PMID   18501082.
  12. ↑ Oudard, Stéphane; Fizazi, Karim; Sengeløv, Lisa; Daugaard, Gedske; Saad, Fred; Hansen, Steinbjørn; Hjälm-Eriksson, Marie; Jassem, Jacek; Thiery-Vuillemin, Antoine (2017-10-01). "Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA". Journal of Clinical Oncology. 35 (28): 3189–3197. doi:10.1200/JCO.2016.72.1068. ISSN   1527-7755. PMID   28753384.
  13. ↑ Vuong, Winston; Sartor, Oliver; Pal, Sumanta K (2014). "Radium-223 in metastatic castration resistant prostate cancer". Asian Journal of Andrology. 16 (3): 348–353. doi: 10.4103/1008-682X.127812 . ISSN   1008-682X. PMC   4023358 . PMID   24713838.
  14. ↑ Crawford, E; Moul, Judd; Sartor, Oliver; Shore, Neal (2015-08-18). "Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: Achieving testosterone levels below 20 ng/dl". Expert Opinion on Drug Metabolism & Toxicology. 11 (9): 1465–1474. doi:10.1517/17425255.2015.1073711. PMID   26293510.
  15. ↑ Sartor, Oliver. "In the News". ProstateCancerResearch.org. Retrieved 6 September 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.